Viatris EBITDA Margin 2010-2024 | VTRS
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Viatris (VTRS) over the last 10 years. The current EBITDA margin for Viatris as of September 30, 2024 is .
| Viatris EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-09-30 | $15.05B | $2.53B | 16.79% |
| 2024-06-30 | $15.24B | $2.76B | 18.12% |
| 2024-03-31 | $15.36B | $3.27B | 21.30% |
| 2023-12-31 | $15.43B | $3.51B | 22.73% |
| 2023-09-30 | $15.47B | $3.99B | 25.77% |
| 2023-06-30 | $15.60B | $4.11B | 26.37% |
| 2023-03-31 | $15.80B | $4.33B | 27.40% |
| 2022-12-31 | $16.26B | $4.64B | 28.54% |
| 2022-09-30 | $16.73B | $4.65B | 27.77% |
| 2022-06-30 | $17.19B | $4.76B | 27.70% |
| 2022-03-31 | $17.65B | $4.76B | 26.96% |
| 2021-12-31 | $17.89B | $4.47B | 25.00% |
| 2021-09-30 | $17.17B | $3.87B | 22.55% |
| 2021-06-30 | $15.60B | $3.28B | 21.03% |
| 2021-03-31 | $13.76B | $2.56B | 18.62% |
| 2020-12-31 | $11.95B | $2.01B | 16.79% |
| 2020-09-30 | $11.51B | $2.75B | 23.92% |
| 2020-06-30 | $11.50B | $2.76B | 24.02% |
| 2020-03-31 | $11.63B | $2.81B | 24.17% |
| 2019-12-31 | $11.50B | $2.74B | 23.78% |
| 2019-09-30 | $11.39B | $2.76B | 24.21% |
| 2019-06-30 | $11.29B | $2.80B | 24.83% |
| 2019-03-31 | $11.25B | $2.89B | 25.67% |
| 2018-12-31 | $11.43B | $3.02B | 26.38% |
| 2018-09-30 | $11.59B | $3.12B | 26.90% |
| 2018-06-30 | $11.72B | $3.04B | 25.94% |
| 2018-03-31 | $11.87B | $3.25B | 27.41% |
| 2017-12-31 | $11.91B | $3.24B | 27.23% |
| 2017-09-30 | $11.94B | $3.09B | 25.87% |
| 2017-06-30 | $12.01B | $2.64B | 22.01% |
| 2017-03-31 | $11.61B | $2.46B | 21.21% |
| 2016-12-31 | $11.08B | $2.22B | 20.06% |
| 2016-09-30 | $10.30B | $2.20B | 21.33% |
| 2016-06-30 | $9.94B | $2.74B | 27.58% |
| 2016-03-31 | $9.75B | $2.56B | 26.28% |
| 2015-12-31 | $9.43B | $2.49B | 26.44% |
| 2015-09-30 | $9.02B | $2.29B | 25.37% |
| 2015-06-30 | $8.41B | $2.06B | 24.48% |
| 2015-03-31 | $7.88B | $1.88B | 23.86% |
| 2014-12-31 | $7.72B | $1.92B | 24.86% |
| 2014-09-30 | $7.45B | $1.77B | 23.81% |
| 2014-06-30 | $7.13B | $1.61B | 22.60% |
| 2014-03-31 | $6.99B | $1.68B | 24.06% |
| 2013-12-31 | $6.91B | $1.65B | 23.91% |
| 2013-09-30 | $6.82B | $1.63B | 23.86% |
| 2013-06-30 | $6.86B | $1.67B | 24.30% |
| 2013-03-31 | $6.85B | $1.62B | 23.73% |
| 2012-12-31 | $6.80B | $1.66B | 24.35% |
| 2012-09-30 | $6.61B | $1.64B | 24.77% |
| 2012-06-30 | $6.38B | $1.54B | 24.09% |
| 2012-03-31 | $6.27B | $1.56B | 24.88% |
| 2011-12-31 | $6.13B | $1.52B | 24.73% |
| 2011-09-30 | $6.03B | $1.35B | 22.39% |
| 2011-06-30 | $5.81B | $1.28B | 22.08% |
| 2011-03-31 | $5.61B | $1.17B | 20.94% |
| 2010-12-31 | $5.45B | $1.14B | 20.99% |
| 2010-09-30 | $5.37B | $1.10B | 20.51% |
| 2010-06-30 | $5.28B | $0.93B | 17.57% |
| 2010-03-31 | $5.18B | $0.90B | 17.45% |
| 2009-12-31 | $5.09B | $0.92B | 18.14% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.576B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $91.424B | 11.34 |
| Cencora (COR) | United States | $47.484B | 17.51 |
| DiDi Global (DIDIY) | China | $23.330B | 0.00 |
| Natera (NTRA) | United States | $21.401B | 0.00 |
| ICON (ICLR) | Ireland | $16.136B | 14.37 |
| Avantor (AVTR) | United States | $13.422B | 20.12 |
| Revvity (RVTY) | United States | $13.376B | 23.24 |
| CochLear (CHEOY) | Australia | $12.844B | 0.00 |
| BioMerieux (BMXMF) | France | $12.666B | 0.00 |
| Solventum (SOLV) | United States | $11.583B | 0.00 |
| Medpace Holdings (MEDP) | United States | $9.789B | 27.58 |
| Doximity (DOCS) | United States | $9.620B | 56.63 |
| Charles River Laboratories (CRL) | United States | $9.516B | 18.39 |
| HealthEquity (HQY) | United States | $8.966B | 48.66 |
| Sonic Healthcare (SKHHY) | Australia | $8.758B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.885B | 32.05 |
| Life Times (LTH) | United States | $5.085B | 33.66 |
| Sotera Health (SHC) | United States | $3.855B | 20.62 |
| Organon (OGN) | United States | $3.757B | 3.79 |
| BrightSpring Health Services (BTSG) | United States | $3.247B | 69.07 |
| Surgery Partners (SGRY) | United States | $2.892B | 32.97 |
| PACS (PACS) | United States | $2.606B | 0.00 |
| Concentras Parent (CON) | United States | $2.581B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.375B | 0.00 |
| Premier (PINC) | United States | $2.143B | 11.15 |
| Alignment Healthcare (ALHC) | United States | $2.126B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.952B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.616B | 42.40 |
| Teladoc Health (TDOC) | United States | $1.537B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.255B | 12.28 |
| CareDx (CDNA) | United States | $1.183B | 0.00 |
| Progyny (PGNY) | United States | $1.164B | 23.57 |
| Establishment Labs Holdings (ESTA) | $1.050B | 0.00 | |
| AMN Healthcare Services Inc (AMN) | United States | $0.954B | 6.46 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| Embecta (EMBC) | United States | $0.778B | 5.18 |
| SBC Medicals (SBC) | United States | $0.677B | 0.00 |
| Agilon Health (AGL) | United States | $0.655B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.647B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.536B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.425B | 0.00 |
| DocGo (DCGO) | United States | $0.410B | 15.46 |
| Enhabit (EHAB) | United States | $0.366B | 31.61 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.326B | 0.00 |
| LifeMD (LFMD) | United States | $0.241B | 0.00 |
| ModivCare (MODV) | United States | $0.223B | 12.09 |
| Sera Prognostics (SERA) | United States | $0.209B | 0.00 |
| Beauty Health (SKIN) | United States | $0.200B | 0.00 |
| Biodesix (BDSX) | United States | $0.180B | 0.00 |
| Nutex Health (NUTX) | United States | $0.156B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.100B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.25 |
| MultiPlan (MPLN) | United States | $0.084B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.054B | 0.00 |
| OncoCyte (OCX) | United States | $0.043B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.08 |
| Co-Diagnostics (CODX) | United States | $0.034B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.030B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.028B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.020B | 0.00 |
| Oncology Institute (TOI) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |